Based on their attractive findings, they recommended that developing exosomal PD-L1 as a blood-based biomarker could be an attractive option, considering the heterogeneity and dynamic changes of PD-L1 expression in tumours and the invasive nature of tumour biopsy [25]. This evidence concerns the gene CD274 and neoplasm.